S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
66,000% upside on tiny biotech? (Ad)
Stock market today: Asian shares mostly lower after Wall St has its worst week in 6 months
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
66,000% upside on tiny biotech? (Ad)
AI is on the world's mind. Is the UN the place to figure out what to do about it?
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
The single greatest medical breakthrough of all time? (Ad)
Canadian autoworkers ratify new labor agreement with Ford
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
66,000% upside on tiny biotech? (Ad)
Stock market today: Asian shares mostly lower after Wall St has its worst week in 6 months
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
66,000% upside on tiny biotech? (Ad)
AI is on the world's mind. Is the UN the place to figure out what to do about it?
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
The single greatest medical breakthrough of all time? (Ad)
Canadian autoworkers ratify new labor agreement with Ford
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
66,000% upside on tiny biotech? (Ad)
Stock market today: Asian shares mostly lower after Wall St has its worst week in 6 months
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
66,000% upside on tiny biotech? (Ad)
AI is on the world's mind. Is the UN the place to figure out what to do about it?
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
The single greatest medical breakthrough of all time? (Ad)
Canadian autoworkers ratify new labor agreement with Ford
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
66,000% upside on tiny biotech? (Ad)
Stock market today: Asian shares mostly lower after Wall St has its worst week in 6 months
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
66,000% upside on tiny biotech? (Ad)
AI is on the world's mind. Is the UN the place to figure out what to do about it?
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
The single greatest medical breakthrough of all time? (Ad)
Canadian autoworkers ratify new labor agreement with Ford
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
NASDAQ:KRTX

Karuna Therapeutics (KRTX) Stock Forecast, Price & News

$166.03
-2.12 (-1.26%)
(As of 09/22/2023 08:52 PM ET)
Compare
Today's Range
$165.99
$169.32
50-Day Range
$166.03
$209.66
52-Week Range
$159.73
$245.00
Volume
127,400 shs
Average Volume
353,088 shs
Market Capitalization
$6.25 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$260.50

Karuna Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
56.9% Upside
$260.50 Price Target
Short Interest
Healthy
3.58% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.99mentions of Karuna Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$6.70 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($11.04) to ($10.94) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.72 out of 5 stars

Medical Sector

82nd out of 962 stocks

Pharmaceutical Preparations Industry

20th out of 453 stocks


KRTX stock logo

About Karuna Therapeutics (NASDAQ:KRTX) Stock

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of mood and anxiety disorders. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

KRTX Price History

KRTX Stock News Headlines

66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Half Year 2023 PureTech Health PLC Earnings Call
This Stock Could Go Up 66% or More.
Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023.  Click here to get his latest buy.  More here.
10 Analysts Have This to Say About Karuna Therapeutics
Karuna Therapeutics (KRTX) Initiated with a Buy at Wells Fargo
Karuna Therapeutics (NASDAQ: KRTX)
H.C. Wainwright Remains a Buy on Karuna Therapeutics (KRTX)
Karuna Therapeutics (KRTX) Receives a Buy from Mizuho Securities
Karuna Therapeutics Announces Leadership Appointments
Karuna Therapeutics (KRTX) Receives a Buy from Morgan Stanley
See More Headlines
Receive KRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Karuna Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KRTX Company Calendar

Last Earnings
8/03/2023
Today
9/24/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KRTX
Fax
N/A
Employees
210
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$260.50
High Stock Price Forecast
$323.00
Low Stock Price Forecast
$209.00
Forecasted Upside/Downside
+56.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
12 Analysts

Profitability

Net Income
$-276,340,000.00
Net Margins
-2,795.96%
Pretax Margin
-5,870.98%

Debt

Sales & Book Value

Annual Sales
$10.64 million
Book Value
$32.78 per share

Miscellaneous

Free Float
32,696,000
Market Cap
$6.25 billion
Optionable
Not Optionable
Beta
1.06
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Andrew Craig MillerDr. Andrew Craig Miller (Age 41)
    Co-Founder & COO
    Comp: $835.4k
  • Dr. Steven M. Paul M.D. (Age 72)
    Pres of R&D, Chief Scientific Officer & Director
    Comp: $1.32M
  • Dr. Stephen K. BrannanDr. Stephen K. Brannan (Age 67)
    Chief Medical Officer
    Comp: $751.75k
  • Dr. Troy A. IgnelziDr. Troy A. Ignelzi (Age 55)
    Exec. Officer
    Comp: $735.95k
  • Mr. William Meury (Age 55)
    Pres, CEO & Director
  • Mr. Jason Parker Brown
    Chief Financial Officer
  • Ms. Mia Kelley J.D.
    VP of Legal Affairs
  • Mr. Jonathan Rosin
    Chief HR Officer
  • Dr. Alan Breier
    Chair of Scientific Advisory Board & Chief Clinical Advisor
  • Dr. Ronald N. Marcus M.D. (Age 65)
    Sr. VP of Medical













KRTX Stock - Frequently Asked Questions

Should I buy or sell Karuna Therapeutics stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Karuna Therapeutics in the last twelve months. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" KRTX shares.
View KRTX analyst ratings
or view top-rated stocks.

What is Karuna Therapeutics' stock price forecast for 2023?

12 equities research analysts have issued 12-month target prices for Karuna Therapeutics' stock. Their KRTX share price forecasts range from $209.00 to $323.00. On average, they expect the company's share price to reach $260.50 in the next twelve months. This suggests a possible upside of 56.9% from the stock's current price.
View analysts price targets for KRTX
or view top-rated stocks among Wall Street analysts.

How have KRTX shares performed in 2023?

Karuna Therapeutics' stock was trading at $196.50 at the beginning of the year. Since then, KRTX shares have decreased by 15.5% and is now trading at $166.03.
View the best growth stocks for 2023 here
.

Are investors shorting Karuna Therapeutics?

Karuna Therapeutics saw a decline in short interest in the month of August. As of August 31st, there was short interest totaling 1,350,000 shares, a decline of 6.9% from the August 15th total of 1,450,000 shares. Based on an average trading volume of 345,500 shares, the days-to-cover ratio is presently 3.9 days.
View Karuna Therapeutics' Short Interest
.

When is Karuna Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our KRTX earnings forecast
.

How were Karuna Therapeutics' earnings last quarter?

Karuna Therapeutics, Inc. (NASDAQ:KRTX) issued its quarterly earnings data on Thursday, August, 3rd. The company reported ($2.75) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.76) by $0.01. The business earned $0.10 million during the quarter, compared to analysts' expectations of $0.42 million. Karuna Therapeutics had a negative trailing twelve-month return on equity of 27.13% and a negative net margin of 2,795.96%. The business's revenue for the quarter was down 98.1% compared to the same quarter last year. During the same period last year, the business earned ($2.17) earnings per share.

What other stocks do shareholders of Karuna Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Karuna Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), AbbVie (ABBV), Pfizer (PFE), Alibaba Group (BABA), Johnson & Johnson (JNJ), AT&T (T), Target (TGT) and Walt Disney (DIS).

When did Karuna Therapeutics IPO?

(KRTX) raised $70 million in an initial public offering on Friday, June 28th 2019. The company issued 4,400,000 shares at $15.00-$17.00 per share. Goldman Sachs, Citigroup and Wells Fargo Securities served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Karuna Therapeutics' stock symbol?

Karuna Therapeutics trades on the NASDAQ under the ticker symbol "KRTX."

Who are Karuna Therapeutics' major shareholders?

Karuna Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Capital International Investors (10.60%), BlackRock Inc. (4.95%), State Street Corp (2.16%), General Atlantic L.P. (1.93%), Geode Capital Management LLC (1.29%) and Alliancebernstein L.P. (1.02%). Insiders that own company stock include Andrew Craig Miller, Atul Pande, James Healy, Jeffrey M Jonas, Laurie J Olson, Laurie J Olson, Puretech Health Llc, Stephen K Brannan, Steven M Paul and Troy A Ignelzi.
View institutional ownership trends
.

How do I buy shares of Karuna Therapeutics?

Shares of KRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Karuna Therapeutics' stock price today?

One share of KRTX stock can currently be purchased for approximately $166.03.

How much money does Karuna Therapeutics make?

Karuna Therapeutics (NASDAQ:KRTX) has a market capitalization of $6.25 billion and generates $10.64 million in revenue each year. The company earns $-276,340,000.00 in net income (profit) each year or ($10.15) on an earnings per share basis.

How many employees does Karuna Therapeutics have?

The company employs 210 workers across the globe.

How can I contact Karuna Therapeutics?

Karuna Therapeutics' mailing address is 33 ARCH STREET SUITE 3110, BOSTON MA, 02110. The official website for the company is karunatx.com. The company can be reached via phone at (857) 449-2244 or via email at investors@karunatx.com.

This page (NASDAQ:KRTX) was last updated on 9/25/2023 by MarketBeat.com Staff

My Account -